SCHEMBL4745792

SCHEMBL4745792

Cc1ccc2c(c1)c(-c1ccc(-c3ccccc3)cc1)cc1c3ccc(C)c4c3c(cc21)-c1ncccc1-4

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCHE P06276 1/20 0.40
LMNA P02545 4/20 0.37
KDM4E B2RXH2 4/20 0.37
MAPT P10636 4/20 0.37
ALDH1A1 P00352 4/20 0.37
NPSR1 Q6W5P4 2/20 0.37
MEN1 O00255 1/20 0.37
RECQL P46063 1/20 0.37
KMT2A Q03164 1/20 0.37
DHODH Q02127 2/20 0.36
PTGS1 P23219 1/20 0.35
PTGS2 P35354 1/20 0.35
POLB P06746 1/20 0.34
PPARG P37231 1/20 0.34
MCL1 Q07820 1/20 0.34
NR2E3 Q9Y5X4 1/20 0.34
NCOR2 Q9Y618 1/20 0.34
HPGD P15428 2/20 0.32
HSP90AA1 P07900 1/20 0.32
FEN1 P39748 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4746317 0.97 DHODH (0.35) BCHELMNAKDM4EMAPTALDH1A1
SCHEMBL4746339 0.95 DHODH (0.36) BCHELMNAKDM4EMAPTALDH1A1
SCHEMBL4745843 0.94 BCHE (0.40) BCHELMNAKDM4EMAPTALDH1A1
SCHEMBL4746312 0.94 BCHE (0.34) BCHELMNAKDM4EMAPTALDH1A1
SCHEMBL4745791 0.92 BCHE (0.37) BCHELMNAKDM4EMAPTALDH1A1
SCHEMBL4746310 0.91 BCHE (0.34) BCHELMNAKDM4EMAPTALDH1A1
SCHEMBL4746389 0.89 DHODH (0.34) BCHELMNAKDM4EALDH1A1DHODH
SCHEMBL4745812 0.88 ALDH1A1 (0.34) BCHEKDM4EALDH1A1DHODHHPGD
SCHEMBL4746387 0.88 DHODH (0.33) BCHELMNAKDM4EALDH1A1DHODH
SCHEMBL4745985 0.87 BCHE (0.33) BCHEALDH1A1TOP2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-8173275-B2 Azaindenochrysene derivative and organic light-emitting device CANON KABUSHIKI KAISHA (JP) 2012-05-08 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE CANON KABUSHIKI KAISHA (JP) 2010-05-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100117526-A1 NOVEL AZAINDENOCHRYSENE DERIVATIVE AND ORGANIC LIGHT-EMITTING DEVICE NR2E3, OR51E2, AZI2 BCHE 376/4885LMNA 4667/4885KDM4E 219/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.